OncLive TV

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

Chih-Yi Liao, MD, discusses key considerations for the selection of single-agent vs combination regimens in frontline metastatic hepatocellular carcinoma.

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.